Gensaic, Inc. is a redosable genomic medicines company spun out of MIT and funded in 2021. It is leveraging Nobel Prize-winning research on phage-display and directed evolution, Gensaic is pioneering a novel class of gene-delivery vehicles called Genetically encoded Nanoparticles (GeNPs). Gensaics first GeNP vehicle is premised on the evolution of M13 phage-derived particles (PDPs), a highly modular system consisting of 3 engineerable capsids and a designer minimal phage DNA (mpDNA) cargo. M13 originates from the microbiome and had been safely administered to human patients for over a decade. PDPs use phage display for targeted tissue delivery and can package > 20kb of genetic information, nearly any human gene. PDPs benefit from scalable and efficient manufacturing in bacterial culture, holding promise for a new era of accessible and affordable genomic medicines. Gensaics current strategic areas of focus for clinical translation are muscle, respiratory, and CNS. Since its inception, Gensaic has established a deep discovery platform, secured a broad intellectual property portfolio, received recognition through four golden ticket competitions from BioMarin, Astellas, Merck, and Novo-Nordisk; and secured its first R&D collaboration in CNS with Ovid Therapeutics.
